References
- 1. World Health Organization, Regional Office for South-East Asia. Guidelines for the diagnosis, treatment and prevention of leprosy. New Delhi: World Health Organization, Regional Office for South-East Asia; 2018.
- 2. Worobec SM. Current approaches and future directions in the treatment of leprosy. Res Rep Trop Med. 2012;3:79-91.10.2147/RRTM.S27395606778130100775
- 3. Setia MS, Shinde SS, Jerajani HR, Boivin JF. Is there a role for rifampicin, ofloxacin and minocycline (ROM) therapy in the treatment of leprosy? Systematic review and meta-analysis. Trop Med Int Health. 2011;16(12):1541-51.10.1111/j.1365-3156.2011.02873.x21914093
- 4. Gautam VP. Treatment of leprosy in India. J Postgrad Med. 2009;55(3):220-4.10.4103/0022-3859.5741019884754
- 5. Lockwood DN, Cunha Mda G. Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally. Lepr Rev. 2012;83(3):241-4.10.47276/lr.83.3.241
- 6. Villahermosa LG, Fajardo TT Jr, Abalos RM, Cellona RV, Balagon MV, Dela Cruz EC, et al. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy. Am J Trop Med Hyg. 2004;70(2):197-200.10.4269/ajtmh.2004.70.197
- 7. Ji B, Sow S, Perani E, Lienhardt C, Diderot V, Grosset J. Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. Antimicrob Agents Chemother. 1998;42(5):1115-20.10.1128/AAC.42.5.11151057559593137
- 8. Oliveira RB, Sampaio EP, Aarestrup F, Teles RM, Silva TP, Oliveira AL, et al. Cytokines and Mycobacterium leprae induce apoptosis in human Schwann cells. J Neuropathol Exp Neurol. 2005;64(10):882-90.10.1097/01.jnen.0000182982.09978.6616215460
- 9. Garrido-Mesa N, Zarzuelo A, Gálvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169 (2):337-52.10.1111/bph.12139365166023441623
- 10. Narang T, Arshdeep, Dogra S. Minocycline in leprosy patients with recent onset clinical nerve function impairment. Dermatol Ther. 2017;30(1):e12404.10.1111/dth.1240427550711